Report reveals 2024's most polluted cities, countries: Which US cities made the list?
The South Asian countries of Pakistan, India and Bangladesh are among the most polluted countries in the world while Australia, New Zealand and Iceland are among the least polluted countries, a new study by IQAir had determined.
IQAir, a Swiss technology company that studies air quality and pollution and specializes in protection against airborne pollutants, released its seventh annual World Air Quality Report Tuesday, which highlighted "alarming trends of the world's most polluted countries, territories, and regions in 2024."
All but one of the world's top 20 most polluted cities last year were in Asia, with the majority of these cities – 13 – in India, the world's most populous country. Neighboring Pakistan followed with four of the most polluted cities, with China and Kazakhstan having one each.
Data from more than 40,000 air quality monitoring stations across 8,954 locations in 138 countries, territories and regions were analyzed by IQAir's air quality scientists for this year's report, IQAir said.
The Excerpt: Could the ocean be our solution to climate change?
"Air pollution remains the greatest environmental threat to human health," the report said, adding 99% percent of the global population lives in areas that do not meet recommended air quality guideline levels, according to the World Health Organization (WHO).
Air pollution is also the second leading global risk factor for death, and the second leading risk factor for deaths among children under five, following malnutrition, because of its significant impact on respiratory and developmental health, as per the WHO.
"Air pollution remains a critical threat to both human health and environmental stability, yet vast populations remain unaware of their exposure levels," Global CEO of IQAir Frank Hammes said in a statement. "Air quality data saves lives. It creates much needed awareness, informs policy decisions, guiding public health interventions, and empowers communities to take action to reduce air pollution and protect future generations."
Only 17% of global cities meet WHO air pollution guidelines, with 126 countries and regions out of 138 exceeding the WHO annual PM2.5 guideline value of 5 micrograms/cubic meters. Here's a look at which countries and regions are the most polluted and which are the least, including in the United States.
While Ontario, California was the most polluted city in the U.S. in 2024, the most polluted major U.S. city was Los Angeles, according to the report. In fact, the top five most polluted cities in the U.S. were in California.
Here a list of the 10 most polluted cities in the U.S.:
Ontario, California
Bloomington, California
Huntington Park, California
San Bernardino, California
Fontana, California
Visalia, California
Mission, Texas
Glendora, California
Hanford, California
Conroe, Texas
Map: How is the air quality near me? Track AQI in the U.S.
Seattle, Washington was the cleanest major city in the U.S., though Waimea, Hawaii was the least polluted regional city in the U.S., which overall ranked 116 on the World Air Quality Report 2024.
Here a list of the 10 least polluted cities in the U.S.:
Waimea, Hawaii
Ocean View, Hawaii
Seaside, California
Stanwood, Washington
Mountain View, Hawaii
Lander, Wyoming
Astoria, Oregon
Tillamook, Oregon
Silverdale, Washington
Kihei, Hawaii
The twenty most polluted countries in the world are:
Chad: More than 18 times higher than the WHO PM2.5 annual guideline.
Bangladesh: More than 15 times higher than the WHO PM2.5 annual guideline.
Pakistan: More than 14 times higher than the WHO PM2.5 annual guideline.
Democratic Republic of the Congo: More than 11 times higher than the WHO PM2.5 annual guideline.
India: More than 10 times higher than the WHO PM2.5 annual guideline.
Tajikistan
Nepal
Uganda
Rwanda
Burundi
Nigeria
Egypt
Iraq
Ghana
Indonesia
Gambia
United Arab Emirates
Bahrain
Uzbekistan
Qatar
Byrnihat in eastern India was the most polluted metropolitan area of 2024, with India home to six of the nine most polluted global cities. The region of Central and South Asia, meanwhile, is home to the top seven most polluted cities in the world.
Here's a list of the 10 most polluted cities in the world:
Byrnihat, India
Delhi, India
Karaganda, Kazakhstan
Mullanpur, India
Lahore, Pakistan
Faridabad, India
N'Djamena, Chad
Loni, India
New Delhi, India
Multan, Pakistan
Only seven countries met WHO's annual average PM2.5 guideline. These include:
Australia
Bahamas
Barbados
Estonia
Grenada
Iceland
New Zealand
The cleanest cities in the world in 2024 include:
Mayaguez, Puerto Rico
Nieuwoudtville, South Africa
Dexter, Oregon, U.S.
Haines, Alaska, U.S.
Chu, Kazakhstan
Hawaiian Ocean View, Hawaii, U.S.
Waimea, Hawaii, U.S.
Volcano, Hawaii, U.S.
Emu River, Australia
Kapaau, Hawaii, U.S.
While there has been notable progress in expanding air quality monitoring across various countries, regions, and territories over the past 12 months with low-cost air quality monitors — used by citizen scientists, researchers, community advocates, and local organizations — proven to be effective tools for data collection, "considerable gaps still exist in government-operated regulatory systems in many parts of the world," IQAir said. For example, in Africa, real-time, publicly accessible air quality monitoring data is so scarce that there is only one monitoring station for every 3.7 million people.
"The World Air Quality Report underscores how this urgent, data-driven approach is crucial in driving policy changes and collective efforts to reduce pollution for future generations," IQAir said in its report.
Saman Shafiq is a trending news reporter for USA TODAY. Reach her at sshafiq@gannett.com and follow her on X and Instagram @saman_shafiq7.
This article originally appeared on USA TODAY: New report reveals 2024's most polluted countries and cities

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Buzz Feed
6 hours ago
- Buzz Feed
Orbital: A Delicious, Jitter-Free Cold Brew Concentrate
If, like me, you love coffee but can't tolerate caffeine (or you are simply looking to cut back on the amount you consume), then you're in luck. The universe has blessed us with a truly sumptuous decaf concentrate from Orbital Coffee. I am not kidding when I say it tastes just as good, if not better, than any cold brew you can buy from even the hippest coffee shop. Those of us who are relegated to drinking decaf every day know that it is rare to find decaffeinated cold brew. I've long resorted to making it at home in a French press, to mixed (mainly poor) results. When the warm weather hits, I become deeply jealous of everyone showing off their tasty cold brew coffee. So when I first heard that Orbital Coffee specializes in decaf blends, and, more specifically, makes a coffee concentrate that is perfect for cold brew, I knew I had to get my hands on it. Orbital uses a chemical-free Swiss water decaffeination process that removes caffeine without stripping it of its natural inherent flavors or infusing it with possibly harmful chemicals. The Ethiopia concentrate has a really rich, smooth and creamy flavor with peach, molasses and brown sugar tasting notes. The Colombia concentrate is slightly juicier, with citrusy notes paired with caramel, dark chocolate and brown sugar for a bright, silky honey finish. I'm absolutely smitten with both of these flavors. They rival the bold flavor and deliciously smooth texture of regular iced coffee or cold brew, but without the jitters. I'd often drink two cups a day and never felt any caffeine-like effects. They're also lower in acidity than the average coffee concentrate, making them easier on the tummy. While both of these concentrates can be warmed and enjoyed hot, I delighted in drinking them over ice. It's so rare that decaf drinkers can enjoy a truly lush and decadent cold brew, sans caffeine. You can snag them at the Orbital website for either $15 or $30, depending on which size you get. The brand does have an Amazon storefront, but as of right now, it's only selling coffee beans there. Hopefully, we'll be able to get the concentrate there one day! Get the Ethiopia concentrate or the Columbia concentrate from Orbital Coffee for $15+ (available in two sizes).
Yahoo
8 hours ago
- Yahoo
Multi-Blood Monitoring System Market is expected to reach USD 3.9 billion by 2034, with a 6.4% CAGR growth
Multi Blood Monitoring System Market Overview 2025-2034 Luton, Bedfordshire, United Kingdom, June 10, 2025 (GLOBE NEWSWIRE) -- The global multi blood monitoring system market is witnessing dynamic expansion, with its value estimated at approximately USD 2.1 billion in 2024, and expected to grow to around USD 3.9 billion by 2034. This translates into a Compound Annual Growth Rate (CAGR) of 6.4% over the forecast period from 2025 to 2034. This growth is primarily fueled by the increasing demand for accurate, efficient, and accessible blood monitoring technologies across various healthcare applications. Download PDF Brochure: These devices are critical in the management of chronic diseases such as diabetes and cardiovascular conditions. As the global burden of such illnesses escalates, particularly among aging populations and across developing regions, the need for real-time, portable, and user-friendly blood monitoring systems has become more urgent than ever. Market Drivers and Opportunities Several underlying factors are contributing to the expansion of this market. Among the most significant drivers is the rising prevalence of chronic diseases. The World Health Organization (WHO) forecasts that by 2030, chronic diseases will account for over 75% of global deaths, highlighting the growing necessity for continuous and reliable health monitoring tools. Moreover, technological advancements in wearable devices, mobile health apps, and telemedicine have revolutionized the way blood monitoring is conducted. These innovations have led to more personalized and preventive healthcare solutions, allowing patients to self-monitor in real-time, often without the need for clinical supervision. This trend is particularly appealing to tech-savvy consumers and younger demographics who are increasingly proactive about their health. Emerging economies also present significant growth potential. With rising healthcare expenditure, expanding middle-class populations, and improving medical infrastructure, regions such as Asia-Pacific, Latin America, and parts of the Middle East are becoming fertile grounds for market expansion. Additionally, the integration of AI and machine learning into monitoring systems is creating opportunities for predictive diagnostics and tailored treatment strategies, revolutionizing the future of personalized medicine. Key Market Challenges Despite its positive growth outlook, the multi blood monitoring system market faces certain challenges. One of the primary obstacles is the complex regulatory landscape. Medical device manufacturers must navigate stringent approval processes, especially in developed regions like North America and Europe. These regulations, although necessary for ensuring safety and efficacy, often delay product rollouts and increase development costs. Supply chain disruptions have also impacted the market, particularly during and after the COVID-19 pandemic. Delays in procuring raw materials, component shortages, and transportation hurdles have affected production timelines and product availability. Furthermore, high costs associated with technologically advanced blood monitoring devices can be a deterrent for adoption, especially in price-sensitive markets. Healthcare providers are often pressured to deliver cost-effective solutions, which can limit investments in premium monitoring systems. Another pressing concern is data security and patient privacy. With the growing digitalization of healthcare and increased reliance on cloud-based data storage, ensuring the protection of sensitive patient information has become paramount. Regulatory frameworks such as HIPAA and GDPR are placing additional burdens on companies to fortify their cybersecurity measures. Market Segmentation Analysis By Product Type The market is segmented into several product categories including continuous glucose monitoring (CGM) systems, blood pressure monitors, cholesterol testing devices, and complete blood count (CBC) test devices. Among these, CGM systems are emerging as the dominant product category, accounting for roughly 35% of market share. The increased prevalence of diabetes globally has significantly contributed to this trend. Blood pressure monitoring devices come in second, capturing an estimated 25% of the market, owing to the widespread incidence of hypertension. Cholesterol testing devices follow with a 15% market share, as more individuals become aware of the risks associated with high cholesterol levels. By End User Hospitals are the largest consumers of multi blood monitoring systems, accounting for nearly 45% of the market share. The growing number of patients and a strong focus on preventive healthcare are driving demand in this segment. Diagnostic laboratories represent the second-largest user group, contributing 30% of market revenue, largely due to the complexity and volume of testing they handle. Homecare settings have gained traction, especially post-pandemic, and currently hold around 20% of the market. The convenience of remote monitoring has been widely appreciated, particularly among the elderly and chronically ill patients who prefer in-home testing. By Technology From a technology standpoint, wearable technologies are transforming the landscape, projected to represent 40% of the market by 2034. These devices offer unmatched convenience and user engagement. Invasive technologies still maintain a solid 45% market share, particularly in clinical environments where precision is critical. Meanwhile, non-invasive technologies are growing steadily and are expected to hold 15% of the market, driven by advancements in optical and sensor-based innovations. By Application Diabetes management remains the top application area, constituting about 50% of the total market. As diabetes rates continue to climb worldwide, the demand for continuous and accurate glucose monitoring devices is increasing proportionally. Cardiovascular monitoring is another important application, making up 30% of the market, while fitness and wellness monitoring is growing rapidly, accounting for around 15% as consumers adopt proactive health strategies. By Distribution Channel In terms of distribution, offline sales still dominate with a 55% market share, primarily due to the preference for in-person consultations and product demonstrations in hospital and clinical settings. Online channels, however, are growing fast and now represent 30% of sales, fueled by digital adoption and e-commerce growth. Direct sales—through specialized distributors—comprise the remaining 15%, ensuring product customization and support services. Browse full Report - Market Segmentation Product Type - Continuous Glucose Monitoring Systems - Blood Pressure Monitoring Devices - Cholesterol Testing Devices - Complete Blood Count Test Devices - Others End-User - Hospitals - Diagnostic Laboratories - Homecare Settings - Research Institutions Technology - Wearable Technology - Non-invasive Technology - Invasive Technology Application - Diabetes Management - Cardiovascular Monitoring - Blood Disorders Management - Fitness and Wellness Monitoring Distribution Channel - Online Sales - Offline Sales - Direct Sales Region - North America - Europe - Asia Pacific - Latin America - Middle East & Africa Regional Outlook Regionally, North America leads the global market, accounting for approximately 40% of total revenues in 2024. This dominance is attributed to advanced healthcare infrastructure, favorable regulatory support, and the presence of leading industry players. Europe follows with a 30% market share, supported by robust public healthcare systems and a rising focus on personalized medicine. The Asia-Pacific region is the fastest-growing market, projected to expand at a CAGR of 7.5%. This growth is driven by large patient populations, increasing disposable income, and government initiatives to enhance healthcare access. Countries such as China, India, and Japan are key contributors to this growth trajectory. Latin America and the Middle East & Africa collectively account for a modest share (5% in 2024) but are poised for steady growth due to improvements in healthcare infrastructure and expanding awareness about chronic disease management. Key Competitors Abbott Laboratories Roche Holding AG Siemens Healthineers Becton, Dickinson and Company (BD) Medtronic plc Nova Biomedical Johnson & Johnson Dexcom, Inc. Arkray, Inc. Ascensia Diabetes Care Terumo Corporation GlySens Incorporated Insulet Corporation Elysium Health LabCorp Recent Industry Developments Several companies have made notable strides in advancing this market: Abbott Laboratories launched FreeStyle Libre 3, a real-time glucose monitor with a discreet sensor, in June 2023, strengthening its lead in the CGM space. In April 2023, Roche formed a strategic partnership with a wearable tech firm to integrate blood monitoring devices with smart devices, enhancing patient engagement and adherence. Siemens Healthineers acquired an AI-based diagnostics company in August 2023, signaling a deeper focus on precision diagnostics through data analytics. Dexcom received FDA approval in September 2023 for a no-fingerstick CGM device, which is likely to broaden its user base and redefine market standards. Medtronic expanded its product line into Asia and Africa in July 2023, targeting underserved markets and accelerating growth in emerging economies. This report is also available in the following languages : Japanese (マルチ血液モニタリングシステム市場), Korean (다혈액 모니터링 시스템 시장), Chinese (多血液监测系统市场), French (Marché des systèmes de surveillance sanguine multi-sang), German (Markt für Multi-Blutüberwachungssysteme), and Italian (Mercato dei sistemi di monitoraggio multi-sangue), etc. Request Sample Pages: More Research Finding – Medical Refrigerated Market The global medical refrigerated market is valued at approximately $6.5 billion in 2024, with projections indicating a potential increase to around $10 billion by 2034. This growth reflects a robust Compound Annual Growth Rate (CAGR) of approximately 4.5% during the forecast period from 2025 to 2034. Cardiovascular Monitoring Devices Market The cardiovascular monitoring devices market is valued at approximately $10.5 billion in 2024, with projections indicating substantial growth, reaching around $16.8 billion by 2034. This translates to a robust Compound Annual Growth Rate (CAGR) of approximately 4.8% during the forecast period from 2025 to 2034. Non Invasive Hemodynamic Detection System Market The global Non-Invasive Hemodynamic Detection System market is valued at approximately USD 2.1 billion in 2024, with strong growth anticipated over the next decade. By 2034, the market is projected to reach around USD 4.5 billion, representing a Compound Annual Growth Rate (CAGR) of approximately 8.0%. Disposable Syringes and Accessories Market The global disposable syringes and accessories market is valued at approximately $7.5 billion in 2024, with a projected growth trajectory that anticipates reaching around $13 billion by 2034. This translates to a compound annual growth rate (CAGR) of about 6.1% over the 2025-2034 period. Blood Collection Mixer Market The blood collection mixer market is valued at approximately $250 million in 2024 and is projected to reach around $400 million by 2034. This growth represents a Compound Annual Growth Rate (CAGR) of about 5.1% during the forecast period from 2025 to 2034. Hemochromatosis Treatment Market The global hemochromatosis treatment market is valued at approximately $2.1 billion in 2024. The market is anticipated to grow significantly, reaching an estimated $3.5 billion by 2034, reflecting a Compound Annual Growth Rate (CAGR) of 5.2% during the forecast period of 2025–2034. Gestational Trophoblastic Disease Market The gestational trophoblastic disease (GTD) market is currently valued at approximately $1.8 billion in 2024, with projections indicating a potential growth to around $3.1 billion by 2034. This represents a compound annual growth rate (CAGR) of approximately 6.2% during the forecast period from 2025 to 2034. Septicemia Diagnostic Market The global septicemia diagnostics market is valued at approximately $1.5 billion in 2024, with projections indicating a growth to around $2.9 billion by 2034. This represents a Compound Annual Growth Rate (CAGR) of about 7.5% for the period from 2025 to 2034. Single Use Safety Lancet Market The global market for single-use safety lancets, valued at approximately $1.2 billion in 2024, is expected to reach around $2.5 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of 7.7% during the forecast period from 2025 to 2034. Microalbuminuria Test Strip Market The microalbuminuria test strip market is poised for notable growth, valued at approximately $1.2 billion in 2024. This market is projected to expand to around $2.4 billion by 2034, indicating a robust growth trajectory. The Compound Annual Growth Rate (CAGR) for the forecast period from 2025 to 2034 is estimated at 7.3%. Monkeypox Virus Detection Reagent Market The monkeypox virus detection reagent market is anticipated to reach approximately $150 million in value by 2024, driven by heightened awareness and diagnostic needs amid ongoing public health surveillance. The market is projected to expand significantly, reaching an estimated $300 million by 2034, reflecting sustained interest in infectious disease diagnostics and preparedness. Blood Tester Market The global blood testing market is anticipated to reach a value of approximately $75 billion in 2024, driven by increasing prevalence of chronic diseases, rising health awareness, and advancements in diagnostic technologies. The market is projected to grow at a Compound Annual Growth Rate (CAGR) of 6.5% from 2025 to 2034, potentially reaching over $135 billion by 2034. HBsAg ELISA Test Kit Market The HBsAg ELISA Test Kit market is poised for robust growth, with a current market value estimated at approximately $1.5 billion in 2024. Driven by the increasing global prevalence of Hepatitis B, ongoing advancements in diagnostic technologies, and rising healthcare expenditures, the market is projected to reach around $2.8 billion by 2034. This trajectory indicates a Compound Annual Growth Rate (CAGR) of approximately 6.5% from 2025 to 2034. Blood Plasma Extractor Market The global blood plasma extractor market is valued at approximately $1.2 billion, driven by rising demand for plasma-derived therapies in treating various diseases. The market is projected to reach about $2.9 billion by 2034, reflecting an impressive Compound Annual Growth Rate (CAGR) of approximately 9.2% from 2025 to 2034. Amphetamine Test Kit Market The amphetamine test kit market is projected to reach a value of approximately $500 million in 2024, with expectations to grow to around $900 million by 2034. This growth reflects a robust Compound Annual Growth Rate (CAGR) of 6% during the forecast period of 2025 to 2034. CONTACT: Irfan Tamboli (Head of Sales) Phone: + 1704 266 3234 Email: sales@ in to access your portfolio


News24
12 hours ago
- News24
New Covid-19 variant being monitored, but no resurgence of cases
Authorities are monitoring a new Covid-19 variant. However, this has not resulted in a resurgence of cases in South Africa. South Africa has also seen a seasonal increase in influenza. Health Minister Aaron Motsoaledi said South Africa is monitoring a new Covid-19 variant, but has not seen a resurgence in cases. Motsoaledi said that the new variant, known as Nimbus or NB.1.8.1, has been linked to a resurgence of cases in parts of Asia. 'The World Health Organisation (WHO) has designated this a variant under monitoring due to its growing presence,' he added. Speaking at the G20 Health Working Group Meeting on Tuesday, Motsoaledi said that South Africa continues to have robust surveillance systems in place. 'Our National Institute for Communicable Diseases (NICD) manages a comprehensive Sentinel Surveillance programme that systematically tests for key respiratory viruses, including SARS-CoV-2, influenza, and RSV. Currently, our data shows very low SARS-CoV-2 activity,' Motsoaledi said. READ | Trying to keep colds and flu's at bay this winter? Here's what you need in your kit He added that while there had been a seasonal increase in influenza, his department was 'well prepared to manage this' and that Covid-19 vaccinations should still prove effective. 'Crucially, the new variant remains a descendant of the Omicron lineage,' he said. This means that current recommendations for updated SARS-CoV-2 vaccines are still effective. Therefore, at this stage, no specific new public health actions are required from the public. 'We continue to advocate for maintaining good hygiene practices – such as handwashing, covering coughs, and staying home when unwell. These simple measures are effective in reducing the spread of all respiratory illnesses. We will continue to monitor the situation closely through our established networks and will report any significant changes.' A circular from the WHO shows that there has been a slight increase in the spread of Covid-19 in some regions due to the new variant. The WHO is closely observing the new variant and said that, while its unique mutations may slightly impact its contagiousness, current Covid-19 vaccines were still expected to provide strong protection. The WHO said there was no evidence that this variant caused more severe illnesses than previous ones.